Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600
Eton Pharmaceuticals, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, […]
Catamaran Bio Selects OmniaBio as Partner to Develop and Manufacture Allogeneic CAR-NK Cell Therapies
Catamaran Bio, a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, and OmniaBio, […]
WAKIX® (Pitolisant) Receives Approval for the Treatment of Narcolepsy in Children Over 6 Years of Age, a Rare, Under-Diagnosed Condition
The European Medicines Agency has just granted an extension of the indication for the marketing […]
Vesigen Therapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance (FARA) to Develop a Targeted Genome Editing Therapeutic Strategy
Vesigen Therapeutics, a biotechnology company developing targeted therapies by engineering a distinct class of human […]
Cantargia Treats First Triple-Negative Breast Cancer Patient in Randomized Phase II Part of TRIFOUR Trial
Cantargia today reported that, following positive results in the lead-in phase of the clinical phase […]
Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU
Telix Pharmaceuticals today announces additional positive results from its completed pivotal Phase III ZIRCON study […]
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI™ (lecanemab-irmb) for Veterans Living with Early Stages of Alzheimer's Disease
BioArctic AB’s partner Eisai announced today that the U.S. Veterans Health Administration (VHA) is providing […]
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE™ for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
Acadia Pharmaceuticals has announced that the United States Food and Drug Administration (FDA) has approved […]
Bio-Thera Solutions Announces First Patient Dosed in Study for the Treatment of Advanced Solid Tumors
Bio-Thera Solutions, a commercial-stage pharmaceutical company, has announced that dosing has begun in a Phase […]
Gene Therapy Candidate for Amyotrophic Lateral Sclerosis (ALS) Demonstrates Bioactivities in a Murine Model of the Disease
Anew Medical, a medical product development company, announced results presented at the European Society of […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more